Cargando…
Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097853/ https://www.ncbi.nlm.nih.gov/pubmed/35793261 http://dx.doi.org/10.1136/annrheumdis-2021-220647corr1 |
| _version_ | 1785024658638110720 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10097853 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100978532023-04-14 Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study Ann Rheum Dis Correction BMJ Publishing Group 2022-07 2022-06-08 /pmc/articles/PMC10097853/ /pubmed/35793261 http://dx.doi.org/10.1136/annrheumdis-2021-220647corr1 Text en © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. |
| spellingShingle | Correction Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study |
| title | Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study |
| title_full | Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study |
| title_fullStr | Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study |
| title_full_unstemmed | Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study |
| title_short | Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study |
| title_sort | correction: immunogenicity and safety of the bnt162b2 mrna covid-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097853/ https://www.ncbi.nlm.nih.gov/pubmed/35793261 http://dx.doi.org/10.1136/annrheumdis-2021-220647corr1 |